The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effects of denosumab on fracture and bone mineral density by level of kidney function
Abstract
The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. We examined incident fracture rates; changes in bone mineral density (BMD), serum calcium, and creatinine; and the incidence of adverse events after 36 months of follow-up in subjects receiving DMAb or placebo, stratified by level of kidney function. We used a subgroup interaction term to determine if there were differences in treatment effect by eGFR. Most (93%) women were white, and the mean age was 72.3 ± 5.2 years; 73 women had an eGFR of 15 to 29 mL/min; 2817, between 30 to 59 mL/min; 4069, between 60 to 89 mL/min, and 842 had an eGFR of 90 mL/min or greater. None had stage 5 CKD. Fracture risk reduction and changes in BMD at all sites were in favor of DMAb. The test for treatment by subgroup interaction was not statistically significant, indicating that treatment efficacy did not differ by kidney function. Changes in creatinine and calcium and the incidence of adverse events were similar between groups and did not differ by level of kidney function. It is concluded that DMAb is effective at reducing fracture risk and is not associated with an increase in adverse events among patients with impaired kidney function. © 2011 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“By blocking the binding of RANKL to RANK, denosumab decreases the number and activity of osteoclasts, decreases bone resorption, and increases bone mineral density (BMD).((9,10)) In postmenopausal women with osteoporosis, as compared with placebo, 36 months of denosumab treatment significantly increased spine, hip, an…”
BackgroundDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationMacLeod, A. M. (2009) · Kidney International · Cited by 2,218
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Levin, A., Bakris, G. L., Molitch, M., Smulders, M., Tian, J., Williams, L. A., & Andress, D. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002009 · Cited by 1,513
Prevalence of low femoral bone density in older U.S. women from NHANES III
Looker, A. C., Johnston, C. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., & Lindsay, R. L. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100517 · Cited by 1,379
Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III
Looker, A. C., Orwoll, E. S., Johnston, C. C., Lindsay, R. L., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., & Heyse, S. P. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.11.1761 · Cited by 1,051
Cited by
(2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.04.001 · Cited by 1,956
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
A single-dose study of denosumab in patients with various degrees of renal impairment
Block, G. A., Bone, H. G., Fang, L., Lee, E., & Padhi, D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1613 · Cited by 340
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Self-citationKetteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., Moe, S. M., Shroff, R., Tonelli, M. A., Toussaint, N. D., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2640 · Cited by 318
Metadata
- Authors
- Jamal, S. A., Ljunggren, Ö., Stehman-Breen, C., Cummings, S. R., McClung, M. R., Goemaere, S., Ebeling, P. R., Franek, E., Yang, Y.-C., Egbuna, O. I., Boonen, S., & Miller, P. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-13
- Volume
- 26
- Issue
- 8
- Pages
- 1829-1835
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1971488797
- Cited by
- 356
- References
- 21
- FWCI
- 26.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of denosumab on fracture and bone mineral density by level of kidney function. https://app.cochat.ai/papers/10.1002/jbmr.403
- The paper
- Jamal, S. A., Ljunggren, Ö., Stehman-Breen, C., Cummings, S. R., McClung, M. R., Goemaere, S., Ebeling, P. R., Franek, E., Yang, Y.-C., Egbuna, O. I., Boonen, S., & Miller, P. D. (2011). Effects of denosumab on fracture and bone mineral density by level of kidney function. Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.